Metallothionein isoforms as double agents - Their roles in carcinogenesis, cancer progression and chemoresistance

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F20%3A43918111" target="_blank" >RIV/62156489:43210/20:43918111 - isvavai.cz</a>

Alternative codes found

RIV/00216305:26620/20:PU136918

Result on the web

<a href="https://doi.org/10.1016/j.drup.2020.100691" target="_blank" >https://doi.org/10.1016/j.drup.2020.100691</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.drup.2020.100691" target="_blank" >10.1016/j.drup.2020.100691</a>

Result language

angličtina

Original language name

Metallothionein isoforms as double agents - Their roles in carcinogenesis, cancer progression and chemoresistance

Original language description

Metallothioneins (MTs) are small cysteine-rich intracellular proteins with four major isoforms identified in mammals, designated MT-1 through MT-4. The best known biological functions of MTs are their ability to bind and sequester metal ions as well as their active role in redox homeostasis. Despite these protective roles, numerous studies have demonstrated that changes in MT expression could be associated with the process of carcinogenesis and participation in cell differentiation, proliferation, migration, and angiogenesis. Hence, MTs have the role of double agents, i.e., working with and against cancer. In view of their rich biochemical properties, it is not surprising that MTs participate in the emergence of chemoresistance in tumor cells. Many studies have demonstrated that MT overexpression is involved in the acquisition of resistance to anticancer drugs including cisplatin, anthracyclines, tyrosine kinase inhibitors and mitomycin. The evidence is gradually increasing for a cellular switch in MT functions, showing that they indeed have two faces: protector and saboteur. Initially, MTs display anti-oncogenic and protective roles; however, once the oncogenic process was launched, MTs are utilized by cancer cells for progression, survival, and contribution to chemoresistance. The duality of MTs can serve as a potential prognostic/diagnostic biomarker and can therefore pave the way towards the development of new cancer treatment strategies. Herein, we review and discuss MTs as tumor disease markers and describe their role in chemoresistance to distinct anticancer drugs.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Drug Resistance Updates

ISSN

1368-7646

e-ISSN

—

Volume of the periodical

52

Issue of the periodical within the volume

September

Country of publishing house

GB - UNITED KINGDOM

Number of pages

13

Pages from-to

100691

UT code for WoS article

000577090400005

EID of the result in the Scopus database

2-s2.0-85087039721